Consequences of mucositis-induced treatment breaks and dose reductions on head and neck cancer treatment outcomes

Journal of Supportive Oncology

Volumn 5, Issue 9 SUPPL. 4, 2007, Pages 23-31

  Rosenthal, David I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTIINFECTIVE AGENT; BLEOMYCIN; CARBOPLATIN; HEMOPOIETIC GROWTH FACTOR; PACLITAXEL; PALIFERMIN; PLACEBO;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL EVALUATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REDUCTION; FRACTIONATION; HEAD AND NECK CANCER; HUMAN; HYPOTENSION; NAUSEA; RADIATION DOSE; REVIEW; STOMATITIS; THERAPY DELAY; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC AGENTS; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; HEAD AND NECK NEOPLASMS; HUMANS; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; STOMATITIS; TREATMENT OUTCOME;

EID: 35648942146     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Sutherland SE, Browman GP. Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analys isofrandomized controlled trials. Int J Radiat Oncol Biol Phys 2001;49:917-930. [11240232]
2. Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 2003;66:253-262. [12742264]
3. Withers HR, Taylor JMG, Maciejewski B. The hazards of accelerated tumour clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131-146. [3390344]
4. Scully C, Sonis S, Diz PD. Oral mucositis. Oral Dis 2006;12:229-241. [16700732]
5. Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2006;(2). CD000978. [16625538]
6. Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer2004;100(9suppl):2026-2046. [15108223]
7. Rosenthal DI, Lewin JS, Eisbruch A. Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol 2006;24:2636-2643. [16763277]
8. Amdur RJ, Li JG, Liu C, Hinerman RW, Mendenhall WM. Unnecessary laryngeal irradiation in the IMRT era. Head Neck 2004;26:257-263. [14999801]
9. Fua TF, Corry J, Milner AD, Cramb J, Walsham SF, Peters LJ. Intensity-modulated radiotherapy for nasopharyngeal carcinoma: clinical correlation of dose to the pharyngo-esophageal axis and dysphagia. Int J Radiat Oncol Biol Phys 2007;67:976-981. [17234360]
10. Trotti A, Garden A, Warde P, et al. A multinational, randomized phase III trial of iseganan HCI oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys 2004;58-674-681. [14967419]
11. Koukourakis M, Hlouverakis G, Kosma L, et al. The impact of overall treatment time on the results of radiotherapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1996;34:315-322. [8567332]
12. Cairo MS. Dose reductions and delays: limitations of myelosuppressive chemotherapy. Oncology (Williston Park) 2000;14(suppl 8):21-31. [11033835]
13. Smith RE.Trends in recommendations for myelosuppressive chemotherapy for the treatment of solid tumors. J Natl Compr Canc Netw 2006;4-649-658. [16884668]
14. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003,98:1531-1539. [14508842]
15. Suwinski R, Withers HR. Time factor and treatment strategies in subclinical disease. Int J Radiat Biol 2003;79.495-502. [14530157]
16. Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. int J Radiat Oncol Biol Phys 2007;68:654-661. [17467926]
17. Suntharalingam M, Haas ML, Van Echo DA, et al. Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas ofthe head and neck. Cancer 2001;91:548-554. [11169937]
18. Tomiak AT, Videtici GM, Stitt LW, et al. Treatment breaks caused by toxicity from concurrent chemoradiation for limited small cell lung cancer decrease survival and local control. Presented at the 42nd Annual Meeting of the American Society of Therapeutic Radiation Oncology. October 22-26, 2000. Boston, Massachusetts. Abstract 2124.
19. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21-92-98. [12506176]
20. Groome PA, O'Sullivan B, Mackillop WJ, et al. Compromised local control due to treatment interruptions and late treatment breaks in early glottic cancer: population-based outcomes study supporting need for intensified treatment schedules. Int J Radiat Oncol Biol Phys 2006;64:1002-1012. [16414205]
21. Wang CC, Efird J, Nakfoor B, Martins P. Local control of T3 carcinomas after accelerated ftactionation - a look at the gap. Int J Radiat Oncol Biol Phys 1995;32:162. Abstract 43.
22. Fu KK, PajakTF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000,48:7-16. [10924966]
23. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-906. [7877646]
24. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-1259. Erratum in: N Engl J Med 1994;331:139. [8080512]
25. Smith G, Fine M, Lenert L, Newbold R. Project ChemoInsights reveals physician practice patterns for adjuvant breast cancer, and compares the dose intensity of CMF, AC, and CAF. Proc Am Soc Clin Ontol 1999;18:296.
26. Vera-Llonch M, Oster G, Hagiwara M, Sonis S. Oral mucositis in patients undergoing radiation treatment forhead and neck carcinoma. Cancer 2006;106:329-336. [16342066]
27. Cox JD, Pajak TF, Marcial VA, et al. Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts: new evidence for accelerated proliferation from Radiation Therapy Oncology Group Protocol 8313. Cancer 1992;69:2744-2748. [1571904]
28. Garden AS, Harris J, Vokes EE, et al. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2004;22:2856-2864. [15254053]
29. Merlano M, Russi EG, Numico G, et al. Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial. Radiother Oncol 2005;75:193-196. [16086909]
30. Bentzen SM, Saunders MI, Dische S, Bond SJ. Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. Radiother Oncol 2001;60:123-135. [11439207]
31. Bourhis J, Lapeyre M,Tortochaux J, et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol 2006;24:2873-2878. [16782926]
32. Elting LS, Cooksley CD, Garden AS. Impact of the use of IMRT on the risk, outcomes, and cost of oral mucositis among recipients of head and neck radiotherapy. Presented at the 19th Annual Multinational Association of Supportive Care in Cancer. June 22-24, 2006. Toronto, Ontario, Canada. Abstract 16-107.
33. Schuchter LM, Hensley ML, Meropol NJ,Winer EP; American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002;20:2895-2903. [12065567]
34. Brizel DM,Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer J Clin Oncol 2000;18:3339-3345. Erratum in: J Clin Oncol 2000;18:4110-4111. [11013273]
35. Koukourakis MI, Kyrias G, Kakolyris S, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 2000;18:2226-2233. [10829042]
36. Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;52:739-747. [11849797]
37. Koukourakis MI, Abatzoglou I, Sivridis L, Tsarkatsi M, Delidou H. Individualization of the subcutaneous amifostine dose during hypofractionated/accelerated radiotherapy. Anticancer Res 2006;26:2437-2443. [16821629]
38. Jellema AP, Slotman BJ, Muller MJ, et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer 2006;107:544-553. [16804929]
39. McDonald S, Meyerowitz C, Smudzin T, Rubin P. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys 1994,29:747-754. [8040020]
40. Bourhis J, De Crevoisier R, Abdulkarim B, et al. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2000,46:1105-1108. [10725619]
41. Rades D, Fehlauer F, Bajrovic A, et al. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiother Oncol 2004;70:261-264. [15064010]
42. Wynn RB, Mehta V. Reduction of treatment breaks and radiation-induced esophagitis and pneumonitis using amifostine in unresectable non-small cell lung cancer patients receiving definitive concurrent chemotherapy and radiation therapy: a prospective community-based clinical trial. Semin Oncol 2005;32(suppl 3):S99-S104. [16015543]
43. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351:2590-2598. [15602019]
44. McCarthy GM, Awde JD, Ghandi H, Vincent M, Kocha WI. Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. Oral Oncol 1998;34:484-490. [9930359]
45. Rosen LS,Abdi E, Davis ID, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 2006;24:5194-5200. [17075109]
46. RTOG Protocol 0435. A randomized, phase III, double-blind, placebo-controlled study to evaluate the efficacy and safety of palifermin for the reduction of oral mucositis in patients with locally advanced head and neck cancer receiving radiation therapy with concurrent chemotherapy (followed by surgery for selected patients). Available at: http://www.rtog.org. Accessed August 25, 2007.
47. Cascinu S, Fedeli A, Luzi Fedeli S, Catalano G. Intensive weekly chemotherapy for advanced gastric cancer using 5-fluorouracil, epi-doxorubicin, 6S-leucovorin and granulocyte-colony stimulating factor. Int J Oncol 1993;3:535-538.
48. Chi KH, Chen CH, Chan WK, et al. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil and leucovorin chemotherapy. J Clin Oncol 1995;13:2620-2628. [7595716]
49. Vokes EE, Haraf DJ, Mick R, et al. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol 1994;12:2351-2359. [7525886]
50. Mascarin M,Franchin G, Minatel E, et al. The effect of granulocyte colony-stimulating factor on oral mucositis in head and neck cancer patients treated with hyperfractionated radiotherapy. Oral Oncol 1999;35:203-208. [10435157]
51. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:1161-1171. [11483325]
52. Sasse AD, Clark LG, Sasse EC, Clark OA. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int J Radiat Oncol Biol Phys 2006;64:784-791. [16198504]
53. Garden AS. Mucositis: current management and investigations. Semin Radiat Oncol 2003;13:267-273. [12903015]
54. Peterson DE, Petit RG. Phase III study: AES-14 in patients at risk for mucositis secondary to anthracycline-based chemotherapy. J Clin Oncol 2004,22(14S).8008.
55. Chambers MS, Welsh V, Scrimger RA, et al. RK-0202 for radiation-induced oral mucositis. J Clin Oncol 2006,24(18S):5523.
56. Veness MJ, Foroudi F, Gebski V, et al. Use of topical misoprostol to reduce radiation-induced mucositis: results of a randomized, double-blind, placebo-controlled trial. Australas Radiol 2006;50:468-474. [16981945]